Complement Activation and Thrombotic Microangiopathies.

Area of Science:

• Nephrology
• Immunology
• Hematology

Background:

• Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy driven by complement pathway dysregulation.
• Complement activation is implicated in other thrombotic microangiopathies.
• Evaluating complement activation is crucial for understanding and treating these conditions.

Purpose of the Study:

• To assess complement activation in various thrombotic microangiopathies.
• To monitor the efficacy of complement inhibition therapies.
• To establish a diagnostic methodology for complement overactivation.

Main Methods:

• Endothelial cells were exposed to patient plasma or sera to detect C5b-9 deposits via immunofluorescence.
• Patients with aHUS, HELLP syndrome, severe preeclampsia, and malignant hypertension were included.
• Eculizumab treatment response was evaluated by measuring C5b-9 deposition.

Main Results:

• Activated plasma from aHUS patients showed increased C5b-9 deposition.
• Eculizumab effectively inhibited C5b-9 deposition in most aHUS patients.
• Elevated C5b-9 deposition was observed in HELLP syndrome and preeclampsia, normalizing over time.
• Malignant hypertension showed complement activation levels similar to controls.

Conclusions:

• The study methodology successfully identifies complement overactivation in aHUS, HELLP syndrome, and preeclampsia.
• This approach can sensitively assess individual C5 inhibition treatment efficiency.
• Complement dysregulation is a common factor in these microangiopathies, offering therapeutic targets.